A secondary , called GLP-1 (glucagon-like peptide-1), boosts insulin production
Generalmente son ms intensos durante las primeras semanas de tratamiento y tienden a disminuir con el tiempo
Safety and Tolerability of Dual-Medication Therapy Metformin and GLP-1 medications have different side-effect profiles, so combining them requires careful monitoring but is generally well-tolerated
A separate ~10,000-patient cardiovascular outcomes trial (TRIUMPH-Outcomes) won't report until 20282029
Realistic expectations, consistent use, and holistic skin care practices are key to seeing long-term benefits
Treatments, including selective serotonin reuptake inhibitors, are efficacious in only a small number of patients, which underscores the need to develop novel, efficient treatments